| ID | 1179 |
| Name of the vaccine | SA3Ag |
| Microbe | Bacteria |
| Disease name | Methicillin-Resistant Staphylococcus aureus (MRSA) |
| Name of bacteria | Staphylococcus aureus |
| Type of vaccine | Polysaccharide |
| Nucleic acid content | Circular DNA |
| Age | 18 to 85 years |
| Description of the vaccine | 3-Antigen S. aureus vaccine. |
| Name of the manufacturer | Pfizer |
| Name of the manufacturing country | Australia |
| Year of manufacture | 2011 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Three doses and a booster. |
| Mechanism of action | Generates antibodies that inhibit the Fg binding of invasive S. aureus. |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For Staphylococcal skin infections. |
| Side effects of vaccine | Mild injection site reactions. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 25707693 |
| Clinical trial number | NCT01018641 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|